

Chlorpheniramine

Selected References:

- Aldridge TD, et al. 2014. First-trimester antihistamine exposure and risk of spontaneous abortion or preterm birth. *Pharmacoepidemiol Drug Saf*, 23(10):1043-50.
- Aselton P, et al. 1985. First-trimester drug use and congenital disorders. *Obstet Gynecol* 65(4):451-455.
- Diav-Citrin O, et al. 2003. Pregnancy outcome after gestational exposure to loratadine or antihistamines: a prospective controlled cohort study. *J Allergy Clin Immunol* 111(6):1239-1243.
- Etwel F, et al. 2017. The Risk of Adverse Pregnancy Outcome After First Trimester Exposure to H1 Antihistamines: A Systematic Review and Meta-Analysis. *Drug Saf*, 40(2):121-132.
- Gilboa SM, et al. 2014. Antihistamines and birth defects: a systematic review of the literature. *Expert Opin Drug Saf*, 13(12):1667-98.
- Gilboa SM, et al. 2009. National Birth Defects Prevention Study: Use of antihistamine medications during early pregnancy and isolated major malformations. *Birth Defects Res A Clin Mol Teratol* 85(2):137-150.
- Hansen C, et al. 2020. Use of antihistamine medications during early pregnancy and selected birth defects: The National Birth Defects Prevention Study, 1997-2011. *Birth Defects Res*, 112(16):1234-1252.
- Hellbom E. 2005. Chlorpheniramine, selective serotonin-reuptake inhibitors (SSRIs) and over-the-counter (OTC) treatment. *Med Hypotheses*. ;66(4):689-90.
- Ito S, et al. 1993. Prospective follow-up of adverse reactions in breastfed infants exposed to maternal medication. *Am J Obstet Gynecol*. 168:1393-1399.
- Jick H, et al. 1981: First-trimester drug use and congenital disorders. *JAMA* 246(4):343-346.
- Koh YP, et al. 2019. New Change in pregnancy and lactation labeling: Review of dermatologic drugs. *Int'l J of Women's Dermatology*, 5(4):216-226
- Li Q et al. 2013. Assessment of antihistamine use in early pregnancy and birth defects. *J Allergy Clin Immunol Pract*. 1(6):666-74.
- Nelson MM and Forfar JJ. 1971. Associations between drugs administered during pregnancy and congenital abnormalities of the fetus. *Br Med J*. 1:523-527.
- Ngo E, et al. 2022. Antihistamine use during breastfeeding with focus on breast milk transfer and safety in humans: A systematic literature review. *Basic Clin Pharmacol Toxicol*, 130(1):171-181.

Mga Tanong? Tumawag sa 866.626.6847 | Mag-text sa 855.999.3525 | Mag-email o Makipag-chat sa [MotherToBaby.org](https://www.MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, January 1, 2025.

Chlorpheniramine

Selected References:

- Arango O, et al. 1996. Reversible azoospermia in a patient treated with triazolam. *Eur J Contracept Reprod Health Care*; 1:293-4.
- Bagger NT, et al. 2023. Perinatal outcomes after therapeutic rest in the latent phase of labor: A cohort study. *Acta obstetrica et gynecologica Scandinavica*, 102(9), 1210-1218.
- Halcion Prescribing Information. Available online at https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/017892s049lbl.pdf. [Accessed Jan 2025]
- Kallen B, et al. 2013. The use of central nervous system active drugs during pregnancy. *Pharmaceuticals* 6(10):1221-1286.
- Kelly LE, et al. 2012. Neonatal benzodiazepines exposure during breastfeeding. *J Pediatr*; 161(3):448-51.
- Matsuo A, et al. 1979. Reproduction studies of triazolam in rats and rabbits. *Iyakuin Kenkyu* 10:52-67.
- Noh Y, et al. 2022. First-trimester exposure to benzodiazepines and risk of congenital malformations in offspring: A population-based cohort study in South Korea. *PLoS Med*; 19(3):e1003945.
- Sakai T, et al. 1996. Triazolam (Halcion) intoxication in a neonate—a first report [letter]. *Eur J Pediatr*; 155:1065-6.

Mga Tanong? Tumawag sa 866.626.6847 | Mag-text sa 855.999.3525 | Mag-email o Makipag-chat sa MotherToBaby.org.

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, January 1, 2025.

Chlorpheniramine

Selected References:

- Aselton P, et al. 1984. First-trimester drug use and congenital disorders. *Obstet Gynecol*,65(4):451- 455.
- Brigstocke S, et.al 2022. **Review of the Safety Profiles of Laxatives in Pregnant Women.** *J Clin Gastroenterol*, 56(3):197-203.
- Greenhalf JO, Leonard HS. 1973. Laxatives in the treatment of constipation in pregnant and breast-feeding mothers. *Practitioner*; 210:259-63.
- Hale, TW. 2012. *Medications and Mothers' Milk*. Fifteenth Edition. Amarillo, TX: Hale Publishing L.P.
- Heinonen OP, et al. 1977. *Birth Defects and Drugs in Pregnancy*. Littleton, Mass.: John Wright-PSG, pp 385, 442.
- Jick H, et al. 1981. First-trimester drug use and congenital disorders. *JAMA*,246(4):343-346.
- Laden S. 2019. OTC Medication Use in Pregnancy and Breastfeeding. *US Pharmacist*, 44(9):16-19
- Lameris AL, et al. 1979. Drug induced alterations in Mg²⁺ homeostasis. *Clinical Science*,123(1):1.
- MacKenzie K, et al. 1990. Three-generation reproduction study with dioctyl sodium sulfosuccinate in rats. *Fundam Appl Toxicol*,15:53-62.
- Mahadevan U, & Kane S. 2006. American Gastroenterological Association Institute technical review on the use of gastrointestinal medications in pregnancy. *Gastroenterology*,131(1):283-311.
- Rungsiprakarn P, et al. 2015. Interventions for treating constipation in pregnancy. *Cochrane Database Syst Rev*, Sep 4;2015(9):CD011448
- Schindler AM. 1984. Isolated neonatal hypomagnesaemia associated with maternal overuse of stool softener. *Lancet*,2:822.
- Thorpe PG, et al. 2013. Medications in the first trimester of pregnancy: most common exposures and critical gaps in understanding fetal risk. *Pharmacoepidemiol Drug Safe*, 22(9): 1013-1018.
- Zielinski R, et al. 2015. Gastrointestinal distress in pregnancy: prevalence, assessment, and treatment of 5 common minor discomforts. *J Perinat Neonatal Nurs*, 29(1):23-31.

Mga Tanong? Tumawag sa 866.626.6847 | Mag-text sa 855.999.3525 | Mag-email o Makipag-chat sa [MotherToBaby.org](https://www.MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, January 1, 2025.

Chlorpheniramine

Selected References:

- American Academy of Pediatrics. 2008. Maternal phenylketonuria. Committee on Genetics. Pediatrics;122:445-9.
- American College of Obstetricians and Gynecologists Committee on Genetics. 2020. ACOG Committee Opinion 802: Management of Women With Phenylalanine Hydroxylase Deficiency (Phenylketonuria). Obstet Gynecol. 135(4):e167-e170.
- Aldámiz-Echevarría L, et al. 2014. A new case of maternal phenylketonuria treated with sapropterin dihydrochloride. Gynecol Endocrinol. 13:1-3.
- Banta-Wright SA, et al. 2014. Breastfeeding infants with phenylketonuria in the United States and Canada. Breastfeeding Medicine, 9(3), 142-148.
- Burgard P, et al. 1997. Neuropsychologic functions of early treated patients with phenylketonuria, on and off Diet: Results of a cross-national and cross-sectional study. Pediatr Res 41(3):368-374.
- Camp KM, et al. 2014. Phenylketonuria Scientific Review Conference: state of the science and future research needs. Mol Genet Metab. 112(2):87-122.
- Cetin I, et al. 1990. Umbilical amino acid concentration in normal and growth-retarded fetuses sampled in utero by cordocentesis. Am J Obstet Gynecol; 162(1):253-261.
- Feillet F, et al. 2014. Use of sapropterin dihydrochloride in maternal phenylketonuria. A European experience of eight cases. J Inherit Metab Dis.
- Fisch RO, et al. 1991. Children of fathers with phenylketonuria: An international survey. J Pediatr 118(5): 39-741.
- Fox-Bacon C, et al. 1997. Maternal PKU and breastfeeding: case report of identical twin mothers. Clin Pediatr 36(9):539-542.
- Grange DK, et al. 2014. Sapropterin dihydrochloride use in pregnant women with phenylketonuria: an interim report of the PKU MOMS sub-registry. Phenylketonuria Demographics Outcomes and Safety (PKUDOS) registry; Maternal Phenylketonuria Observational Program (PKU MOMS) sub-registry. Mol Genet Metab. 112(1):9-16.
- Grohmann-Held K, et al. 2022. Impact of pregnancy planning and preconceptional dietary training on metabolic control and offspring's outcome in phenylketonuria. J Inherit Metab Dis; 45(6): 1070- 1081.
- Güttler F, et al. 1990. Cognitive development in offspring of untreated and preconceptionally treated maternal phenylketonuria. J Inherit Metab Dis. 13(4):665-71.
- Kenneson A, Borth MI, et al. 2024. Characteristics and outcomes of pregnancies among women with phenylketonuria from the NBS Connect registry. Mol Genet Metab Rep; 39:101092.
- Koch R, et al. 2003. The Maternal Phenylketonuria International Study: 1984-2002. Pediatrics 112(suppl): 1523-1529.
- Koch R, et al. 2005. Tetrahydrobiopterin and maternal PKU. Mol Gen Met 86: S139-S141.
- Koch R, et al. 2010. Psychosocial issues and outcomes in maternal PKU. Mol Genet Metab. 99 Suppl 1:S68-74.
- Kose E, et al. 2017. The effects of breastfeeding in infants with Phenylketonuria. J Pediatr Nurs; 38:27-32.
- Lenke RR and Levy HL. 1980. Maternal phenylketonuria and hyperphenylalanemia: An international survey of the outcome of untreated and treated pregnancies. NEJM 303(21):1202-1208.
- Levy HL, et al. 1991. Paternal phenylketonuria. J Pediatr 118(5):741-743.
- Levy HL, et al. 1996. Fetal ultrasonography in maternal PKU. Prenat Diagn 16:599-604.
- Levy HL & Ghavami M. 1996. Maternal phenylketonuria: a metabolic teratogen. Teratology. 53(3):176-84.
- Lichter-Konecki, U, et al. 2019. Phenylketonuria: Current Treatments and Future Developments. Drugs 79,

495-500

- Maillot, F, et al. 2007. A practical approach to maternal phenylketonuria management. *J Inherit Metab Dis.* 30, 198-201.
- Michals-Matalon K et al. 2003. Role of nutrition in pregnancy with phenylketonuria and birth defects. *Pediatrics* 112(suppl): 1534-1536.
- Nielsen MR, Jørgensen C, et al. 2023. The impact of phenylalanine levels during pregnancy on birth weight and later development in children born to women with phenylketonuria. *J Inherit Metab Dis*; 46(4):586-594.
- Platt LD, et al. 2000. The international study of pregnancy outcome in women with maternal phenylketonuria: report of a 12-year study. *American journal of obstetrics and gynecology*, 182(2), 326-333.
- Prick BW, et al. 2012. Maternal phenylketonuria and hyperphenylalaninemia in pregnancy: pregnancy complications and neonatal sequelae in untreated and treated pregnancies. *Am J Clin Nutr* 95:374-382.
- Rouse B, et al. 1997. Maternal phenylketonuria Collaborative Study (MPUCS) offspring: Facial anomalies, malformations, and early neurological sequelae. *Am J Med Genet* 69:89-95.
- Rouse B & Azen C. 2004. Effect of high maternal blood phenylalanine on offspring congenital anomalies and developmental outcome at ages 4 and 6 years: the importance of strict dietary control preconception and throughout pregnancy. *J Pediatr* 144:235-239.
- Schmidt E, et al. 1994. Sustained attention in adult phenylketonuria: the influence of the concurrent phenylalanine-blood level. *J Clin Exp Neuropsych* 16(5):681-688.
- Singh RH, et al. 2014. Recommendations for the nutrition management of phenylalanine hydroxylase deficiency. *Genet Med* 16:121-123.
- Smith WE, Berry SA, et al. 2025. Phenylalanine hydroxylase deficiency diagnosis and management: A 2023 evidence-based clinical guideline of the American College of Medical Genetics and Genomics (ACMG). **Genet Med**; 27(1):101289.
- Teissier R, et al. 2012. Maternal phenylketonuria: low phenylalaninemia might increase the risk of intra uterine growth retardation. *AFDPHE (Association Française pour le Dépistage et la Prévention des Handicaps de l'Enfant)*. *J Inherit Metab Dis* ;35:993-9.
- Trefz FK, et al. 2003. Potential role of tetrahydrobiopterin in the treatment of maternal phenylketonuria. *Pediatrics* 112(suppl): 1566-1569.
- Van Rijn M, et al. 2003. A different approach to breast-feeding of the infant with phenylketonuria. *Eur J Pediatr* 162:323-326.
- van Wegberg, A.M.J., et al. 2017. The complete European guidelines on phenylketonuria: diagnosis and treatment. *Orphanet J Rare Dis* (12) 162.
- Vockley J, et al. 2014. Phenylalanine hydroxylase deficiency: diagnosis and management guideline. *Genetics in Medicine*, 16(2), 188.
- Waisbren SE, et al. 2014. Maternal phenylketonuria: long-term outcomes in offspring and post-pregnancy maternal characteristics. In *JIMD Reports*, Volume 21 (pp. 23-33).
- Wambach K & Riordan J. 2016. *Breastfeeding and human lactation*. Jones & Bartlett Learning.
- Weglage J, et al. 2001. Normal clinical outcome in untreated subjects with mild hyperphenylalaninemia. *Pediatr Res* 49:532-536.
- Widaman KF, Azen C. 2003. Relation of prenatal phenylalanine exposure to infant and childhood cognitive outcomes: results from the International Maternal PKU Collaborative Study. *Pediatrics*;112:1537-43.

Mga Tanong? Tumawag sa 866.626.6847 | Mag-text sa 855.999.3525 | Mag-email o Makipag-chat sa [MotherToBaby.org](https://www.MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, January 1, 2025.

Chlorpheniramine

Selected References:

- Alsenaid A, Prinz JC. 2016. Inadvertent pregnancy during ustekinumab therapy in a patient with plaque psoriasis and impetigo herpetiformis. *J Eur Acad Dermatol Venereol*. 30(3):488-90.
- American Academy of Pediatrics. 2018. Report of the Committee of Infectious Disease. RedBook. p704.
- Andrulonis R, Ferris LK. 2012 Treatment of severe psoriasis with ustekinumab during pregnancy. *J Drugs Dermatol*. 11(10):1240.
- Avni-Biron, I., et al. 2022. Ustekinumab during pregnancy in patients with inflammatory bowel disease: a prospective multicentre cohort study. *Alimentary pharmacology & therapeutics*, 56(9), 1361–1369.
- Beaulieu D, et al. 2018. Use of Biologic Therapy by Pregnant Women with Inflammatory Bowel Disease does Not affect Infant Response to Vaccines. *Clin Gast & Hep*; 16:99-105.
- Chaparro Sanchez M, et al. 2022. Live vaccines in children exposed to biological agents for IBD in utero and/or during breastfeeding: Are they safe? Results from the Dumbo registry of GETECCU. *United European Gastroenterol J* 2022;10:757-8.
- Chugh, R., et al. 2024. Maternal and Neonatal Outcomes in Vedolizumab- and Ustekinumab-Exposed Pregnancies: Results From the PIANO Registry. *The American journal of gastroenterology*, 119(3), 468–476.
- Ernest-Suarez, K., et al. 2024. Live Rotavirus Vaccination Appears Low-risk in Infants Born to Mothers With Inflammatory Bowel Disease on Biologics. *Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association*, S1542-3565(24)00677-3.
- Fitzpatrick, T., et al. 2023. Immunological effects and safety of live rotavirus vaccination after antenatal exposure to immunomodulatory biologic agents: a prospective cohort study from the Canadian Immunization Research Network. *The Lancet. Child & adolescent health*, 7(9), 648–656.
- Fotiadou C, et al. 2012. Spontaneous abortion during ustekinumab therapy. *J Dermatol Case Rep*. 6(4):105-107.
- Galli-Novak E, et al. 2016. Successful pregnancy outcome under prolonged ustekinumab treatment in a patient with Crohn's disease and paradoxical psoriasis. *J Eur Acad Dermatol Venereol*. 30(12):e191-e192.
- Galluzzo M, et al. 2019. Psoriasis in pregnancy: case series and literature review of data concerning exposure during pregnancy to ustekinumab. *J Dermatolog Treat*. 2019 Feb;30(1):40-44.
- Gisbert J, Chaparro M. 2020. Safety of New Biologics (Vedolizumab and Ustekinumab) and Small Molecules (Tofacitinib) During Pregnancy: A Review. *Drugs* 2020 Jul; 80(11):1085-1100.
- Gorodensky, J. H., Bernatsky, S., Afif, W., St-Pierre, Y., Filion, K. B., & Vinet, É. (2023). Assessing Serious Infections in Children Exposed In Utero to Ustekinumab. *The Journal of rheumatology*, jrheum.2022-1271.
- Gotestam Skorpen C, et al. 2016. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. *Ann Rheum Dis*. 75:795-810.
- Grosen, A., et al. 2022. Normal Sperm DNA Integrity in Patients With Inflammatory Bowel Disease on Ustekinumab Maintenance Therapy. *Inflammatory bowel diseases*, 28(10), 1603–1606.

- Jeong, Y. D. et al. 2024. Biologics Use for Psoriasis during Pregnancy and Its Related Adverse Outcomes in Pregnant Women and Newborns: Findings from WHO Pharmacovigilance Study. *International archives of allergy and immunology*, 1-15.
- Julsgaard, M., et al. 2025. Infant Ustekinumab Clearance, Risk of Infection, and Development After Exposure During Pregnancy. *Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association*, 23(1), 134-143.
- Klenske E, et al. 2019. Drug Levels in the Maternal Serum, Cord Blood and Breast Milk of a Ustekinumab-Treated Patient with Crohn's Disease. *J Crohns Colitis*. 2019 Feb 1;13(2):267-269.
- Lund T and Thomsen SF. 2017. Use of TNF-inhibitors and ustekinumab for psoriasis during pregnancy: a patient series. *Dermatologic Therapy* 30:e12454.
- Mahadevan U, et al. 2017. Drug Safety and Risk of Adverse Outcomes for Pregnant Patients With Inflammatory Bowel Disease. *Gastroenterology*. 152(2):451-462.e2.
- Mahadevan U, et al. 2019. Inflammatory Bowel Disease in Pregnancy Clinical Care Pathway: A Report From the American Gastroenterological Association IBD Parenthood Project Working Group. *Amer J of Obstetrics and Gynecology*. 2019 April; 220(4):308-323.
- Mahadevan, U., et al. 2022. Pregnancy outcomes following periconceptional or gestational exposure to ustekinumab: Review of cases reported to the manufacturer's global safety database. *Alimentary pharmacology & therapeutics*, 56(3), 477-490. <https://doi.org/10.1111/apt.16960>
- Martin PL, et al. 2010. Development in the cynomolgus macaque following administration of ustekinumab, a human anti-IL-12/23p40 monoclonal antibody, during pregnancy and lactation. *Birth Defects Res B Dev Reprod Toxicol*. 89(5):351-363.
- Matro R, et al. 2018. Exposure concentrations of infants breastfed by women receiving biologic therapies for inflammatory bowel disease and effects of breastfeeding on infections and development. *Gastroenterology* 155:696-704.
- Meserve, J., 2021. Paternal Exposure to Immunosuppressive and/or Biologic Agents and Birth Outcomes in Patients With Immune-Mediated Inflammatory Diseases. *Gastroenterology*, 161(1), 107-115.e3.
- Meyer, A., et al. 2025. Safety of Vedolizumab and Ustekinumab Compared With Anti-TNF in Pregnant Women With Inflammatory Bowel Disease. *Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association*, 23(1), 144-153.e22.
- Mitrova, K., et al. 2022. Safety of Ustekinumab and Vedolizumab During Pregnancy-Pregnancy, Neonatal, and Infant Outcome: A Prospective Multicentre Study. *Journal of Crohn's & colitis*, 16(12), 1808-1815.
- Prentice, R., et al. 2025. Vedolizumab and Ustekinumab Levels in Pregnant Women With Inflammatory Bowel Disease and Infants Exposed In Utero. *Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association*, 23(1), 124-133.e7
- Rocha K, et al. 2015. Pregnancy during ustekinumab treatment for severe psoriasis. *Dermatology*; 231:103-104.
- Rosen M, et al. 2012. A case of ustekinumab for the treatment of Crohn's disease during pregnancy [abstract]. *Amer J Gastroenterol*. 107(suppl 1):S516.
- Rowan CR, et al. 2018. Ustekinumab drug levels in maternal and cord blood in a woman with Crohn's Disease treated until 33 weeks of gestation. *Journal of Crohn's and Colitis*;376-378
- Sánchez-García, V., et al. 2023. Exposure to biologic therapy before and during pregnancy in patients with psoriasis: Systematic review and meta-analysis. *Journal of the European Academy of Dermatology and Venereology : JEADV*, 37(10), 1971-1990.
- Sheeran C, Nicolopoulos J. 2014. Pregnancy outcomes of two patients exposed to ustekinumab in the first trimester. *Australasian J of Dermatology*; 55(3);235-236.
- Wils P, et al. 2021. Safety of ustekinumab or vedolizumab in pregnant inflammatory bowel disease patients: a multicentre cohort study. *Aliment Pharmacol Ther*; 53(4):460-470.

Mga Tanong? Tumawag sa 866.626.6847 | Mag-text sa 855.999.3525 | Mag-email o Makipag-chat sa [MotherToBaby.org](https://www.MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, January 1, 2025.